Roy A Whitfield - Net Worth and Insider Trading
Roy A Whitfield Net Worth
The estimated net worth of Roy A Whitfield is at least $34 Million dollars as of 2024-05-06. Roy A Whitfield is the Director of Incyte Corp and owns about 621,082 shares of Incyte Corp (INCY) stock worth over $33 Million. Roy A Whitfield is the Director of Illumina Inc and owns about 2,853 shares of Illumina Inc (ILMN) stock worth over $336,454. Roy A Whitfield is also the Director of Nektar Therapeutics and owns about 197,000 shares of Nektar Therapeutics (NKTR) stock worth over $309,290. Details can be seen in Roy A Whitfield's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Roy A Whitfield has not made any transactions after 2018-06-06 and currently still holds the listed stock(s).
Transaction Summary of Roy A Whitfield
Roy A Whitfield Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Roy A Whitfield owns 3 companies in total, including Nektar Therapeutics (NKTR) , Illumina Inc (ILMN) , and Incyte Corp (INCY) .
Click here to see the complete history of Roy A Whitfield’s form 4 insider trades.
Insider Ownership Summary of Roy A Whitfield
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NKTR | Nektar Therapeutics | 2018-06-06 | director |
| ILMN | Illumina Inc | 2016-08-12 | director |
| INCY | Incyte Corp | 2013-11-18 | director & other: Chairman |
Roy A Whitfield Latest Holdings Summary
Roy A Whitfield currently owns a total of 3 stocks. Among these stocks, Roy A Whitfield owns 621,082 shares of Incyte Corp (INCY) as of November 18, 2013, with a value of $33 Million and a weighting of 98.1%. Roy A Whitfield owns 2,853 shares of Illumina Inc (ILMN) as of August 12, 2016, with a value of $336,454 and a weighting of 0.99%. Roy A Whitfield also owns 197,000 shares of Nektar Therapeutics (NKTR) as of June 6, 2018, with a value of $309,290 and a weighting of 0.91%.
Latest Holdings of Roy A Whitfield
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| INCY | Incyte Corp | 2013-11-18 | 621,082 | 53.76 | 33,389,368 |
| ILMN | Illumina Inc | 2016-08-12 | 2,853 | 117.93 | 336,454 |
| NKTR | Nektar Therapeutics | 2018-06-06 | 197,000 | 1.57 | 309,290 |
Holding Weightings of Roy A Whitfield
Roy A Whitfield Form 4 Trading Tracker
According to the SEC Form 4 filings, Roy A Whitfield has made a total of 0 transactions in Incyte Corp (INCY) over the past 5 years. The most-recent trade in Incyte Corp is the sale of 50,000 shares on November 18, 2013, which brought Roy A Whitfield around $2 Million.
According to the SEC Form 4 filings, Roy A Whitfield has made a total of 0 transactions in Illumina Inc (ILMN) over the past 5 years. The most-recent trade in Illumina Inc is the sale of 4,000 shares on August 12, 2016, which brought Roy A Whitfield around $668,880.
According to the SEC Form 4 filings, Roy A Whitfield has made a total of 0 transactions in Nektar Therapeutics (NKTR) over the past 5 years. The most-recent trade in Nektar Therapeutics is the acquisition of 5,000 shares on June 6, 2018, which cost Roy A Whitfield around $290,200.
Insider Trading History of Roy A Whitfield
- 1
Roy A Whitfield Trading Performance
GuruFocus tracks the stock performance after each of Roy A Whitfield's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Roy A Whitfield is 45.55%. GuruFocus also compares Roy A Whitfield's trading performance to market benchmark return within the same time period. The performance of stocks bought by Roy A Whitfield within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Roy A Whitfield's insider trading performs compared to the benchmark.
Performance of Roy A Whitfield
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 1.75 | | | | | |
| Relative Return to S&P 500(%) | 1.5 | | | | | |
Roy A Whitfield Ownership Network
Roy A Whitfield Owned Company Details
What does Nektar Therapeutics do?
Who are the key executives at Nektar Therapeutics?
Roy A Whitfield is the director of Nektar Therapeutics. Other key executives at Nektar Therapeutics include SVP & General Counsel Mark Andrew Wilson , Chief R&D Officer Jonathan Zalevsky , and director & President & CEO Howard W Robin .
Nektar Therapeutics (NKTR) Insider Trades Summary
Over the past 18 months, Roy A Whitfield made no insider transaction in Nektar Therapeutics (NKTR). Other recent insider transactions involving Nektar Therapeutics (NKTR) include a net sale of 137,918 shares made by Howard W Robin , a net sale of 62,098 shares made by Jonathan Zalevsky , and a net sale of 46,514 shares made by Mark Andrew Wilson .
In summary, during the past 3 months, insiders sold 36,653 shares of Nektar Therapeutics (NKTR) in total and bought 0 shares, with a net sale of 36,653 shares. During the past 18 months, 276,610 shares of Nektar Therapeutics (NKTR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 276,610 shares.
Nektar Therapeutics (NKTR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Nektar Therapeutics Insider Transactions
Roy A Whitfield Mailing Address
Above is the net worth, insider trading, and ownership report for Roy A Whitfield. You might contact Roy A Whitfield via mailing address: C/o Incyte Corporation, 3160 Porter Drive, Palo Alto Ca 93404.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
